Inclusion Criteria:

Subjects will be eligible for inclusion in the study if all of the following criteria are
met:

1. Low risk prostate cancer diagnosed using one transrectal ultrasound guided biopsy
(TRUS)using from 10 to 24 cores within 12 months of enrolment, and showing the
following:

- Gleason 3 + 3 prostate adenocarcinoma as a maximum,

- Two (2) to three (3) cores positive for cancer

- A maximum cancer core length of 5 mm in any core.

2. Cancer clinical stage up to T2a (pathological or radiological up to T2c disease
permitted)

3. Serum prostate specific antigen (PSA) of 10 ng/mL or less

4. Prostate volume equal or greater than 25 cc and less than 70 cc.

5. Male subjects aged 18 years or older.

Exclusion Criteria:

Subjects will not be eligible for the study if meeting any of the following criteria:

1. Unwillingness to accept randomisation to either of the two arms of the study

2. Any prior or current treatment for prostate cancer, including surgery, radiation
therapy (external or brachytherapy) or chemotherapy.

3. Any surgical intervention for benign prostatic hypertrophy

4. Life expectancy less than 10 years.

5. Any condition or history of illness or surgery that may pose an additional risk to
men undergoing the VTP procedure.

6. Participation in another clinical study or recipient of an investigational product
within 1 month of study entry.

7. Subject unable to understand the patient's information document, to give consent or
complete the study tasks. Subject in custody and or in residence in a nursing home or
rehabilitation facility

8. Contra-indication to Magnetic resonance Imaging (MRI) (e.g., pacemaker, history of
allergic reaction to gadolinium), or factors excluding accurate reading of pelvic MRI
(e.g., hip prosthesis)